Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company (NASDAQ:ALT)

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?In my last note on Altimmune, Inc. ( ALT ) back in late August, I made the bull case for its stock. I discussed the Gaithersburg, Maryland based biotech's lead and only drug candidate, pemvidutide, andEdmund Ingham ...